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The increase in PLA2 activity with bacterial infec­
tion of the peritoneal cavity is not unexpected; stud­
ies have documented an increase in PLA2 in chronic 
inflammatory states, acute bacterial infections, and 
system ic sepsis. Patients with bacteremia, sepsis 
syndrome, and malaria have high plasma PLA2 ac­
tivity which correlates with the hemodynamic changes 
and pulmonary dysfunction (9,10). Furthermore, the 
local and systemic manifestations of inflammation 
can be induced by the administration of exogenous 
purified PLA2.
The clinical importance of these observations re­
mains unknown. There is significant evidence that the 
presence of phosphatidylcholine plays a role in facilitat­
ing peritoneal ultrafiltration (11,12). Degradation of 
phosphatidylcholine would thus be associated with 
impaired ultrafiltration. Phospholipase A2 catalyzes 
the hydrolysis of phosphatidylcholine to lyso-phospha- 
tidylcholine. We speculate that high intraperitoneal 
PLA2 activity in renal failure, especially during perito­
nitis, hydrolyzes phosphatidylcholine and contributes 
to the decreased peritoneal ultrafiltration. This action 
may be at least partially responsible for the ultrafil­
tration failure during peritonitis. Furthermore, lyso- 
phosphatidylclioline is a vasoactive substance and may 
be contributory to intraperitoneal vasodilatation, part 
of the local inflammatory reaction.
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The Necessity of Adjusting Dialysate 
Volume to Body Surface Area in Pediatric 
Peritoneal Equilibration Tests
Peritoneal dialysis is an established therapy for 
end-stage renal failure in both adult and pediatric 
patients. Transport kinetics in adult patients is stand­
ardized by using the peritoneal equilibration test 
(PET) as prescribed by Twardowski (1), Standard 
dwell volumes of 2 L are generally used regardless of 
the patient’s size. In pediatric clinical practice a 
volume of 30 -  50 mL/kg body weight (BW) is used in 
most centers. Since the surface area of the peritoneal 
membrane is related to the body surface area (BSA) 
it would be more logical to prescribe dialysate vol­
umes on the basis of BSA. In the present study, PETs 
were performed using an intraperitoneal volume of 
1200 mL/m2. The fluid kinetics were compared to the 
results of the previous PETs in which the volume was
40 mL/kg BW (2),
PATIENTS AND METHODS
Study group A consisted of 13 children (7 boys, 6 
girls) with a median age of 8.3 years (range 3 -  15.9 
years). The median duration of CAPD was 9.4 months 
(range 1 -9 1  months). The intraperitoneal volume in
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Group A was 1211 ± 47 mL/m2, The control group 
(Group B) consisted of 13 children (10 boys, 3 girls) 
with a median age of 7 years (range 3.1 -  15.4 years) 
and a median duration of CAPD of 27.5 months 
(range 1 -  101 months). The intraperitoneal volume 
in this group was 40.3 ± 0.3 mL/kg BW. Four pa­
tients were studied in both groups. The two groups 
were similar with respect to height (118 ± 25 cm vs 
123 ± 24 cm), weight (24 ± 12 kg vs 25 ± 11 kg), and 
BSA (0.88 ± 0.29 m2 vs 0.92 ± 0.28 m2).
In both groups, the PETs were performed as de­
scribed earlier (2). A 4-hour dwell of Dianeal 3.86% 
(Baxter Inc., Deerfield, IL, U.S.A.) was studied using 
Dextran 70 (Macrodex NPBI, Emmercompascuum, 
The Netherlands) as a volume marker. Transcapillary 
ultrafiltration (TCUF) and marker clearance (MC) 
were calculated (2). The protocol was approved by the 
committee of medical ethics of the University Hospi­
tal of Nijmegen and informed consent was obtained.
All data are expressed as mean ± SD. Statistical 
comparisons between the groups were performed 
using the unpaired t-test. Correlations were calcu­
lated by the method of least squares (Pearson). Any 
p values less than 0.05 were considered significant.
RESULTS
The mean (±SD) intraperitoneal volume in mL/kg 
BW in Group A was 46.4 ± 6.0 versus 40.3 ± 0.3 in 
Group B (p = 0.005). The intraperitoneal volume in 
mL/m2 in Group A was 1211 ± 47 versus 1055 ± 141 
in Group B (p = 0.008).
Figure 1 shows the changes in TCUF and MC 
during the 4-hour dwell in both groups. The differ­
ences noted at each dwell time are not significant.
SHORT REPORTS
Cumulative TCUF during the 4-hour dwell was 935 ± 
202 mL/1.73 m2 in Group A and 823 ±226 mL/1.73 m2 
in Group B (p = 0.27), Cumulative MC during the 4- 
hour dwell was 438 ± 275 mL/1.73 m2 in Group A 
versus 307 ± 176 mL/1.73 m2 in Group B (p = 0.67),
Figure 2 shows the relationship between the age of 
the patient and the cumulative TCUF during the 4- 
hour dwell. In Group B there was a positive correla­
tion between age and cumulative TCUF (r = 0.68; p = 
0.01). In Group A there was no correlation between age 
and cumulative TCUF (r = 0.32; p = 0,28). No correla­
tion between age and MC existed in either group.
DISCUSSION
In pediatric PETs different intraperitoneal vol­
umes are applied. Some investigators have used 
intraperitoneal volumes scaled to body weight (3,4), 
body surface area (5), or both (6,7), By using a dwell 
volume of 33 ± 6 mL/kg Mendley and Majkowski (4) 
concluded that glucose equilibration occurs more 
rapidly in younger children. When Kohaut et ctL 
performed PETs in their patients with a dwell vol­
ume related to BW and with a dwell volume related 
to body surface area, age dependency for glucose 
equilibration existed in patients where dwell vol­
umes were prescribed scaled to B W, but disappeared 
in patients where the dwell volume was scaled to 
BSA (6). So we suggested that, for the purpose of 
kinetic studies, the best way to perform PETs is to 
prescribe intraperitoneal volumes based upon BSA, 
as also proposed by other authors (8-10), As ex­
pected, in our study fluid kinetics are independent of 
age in children older than 3 years when prescribing 
intraperitoneal volumes related to BSA.
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Figure 1  The time course of transcapillary ultrafiltration (closed triangles) and marker clearance (+) in Group A (left) and 
Group B (right) in mL/1.73 m2.
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transcapillary ultrafiltration in Group A and Group B.
Fluid kinetics in both groups are not significantly 
different. The tendency toward a higher cumulative 
TCUF and MC in Group A is due to a significantly 
higher intraperitoneal volume in Group A compared 
to Group B. The difference in TCUF cannot be ex­
plained by the use of hypertonic dialysis solution 
since the PETs in both groups were performed with 
glucose 3,86 %.
Although not significantly different it is tempting to 
speculate on the higher MC in Group A. The slight 
increase in MC could be due to a higher intraperitoneal 
pressure in Group A (11). A positive correlation be­
tween intraperitoneal volume and intraperitoneal pres­
sure is postulated (12,13), In a small group of patients 
where PETs were performed using an intraperitoneal 
volume of 1200 mL/m2, hydrostatic intraperitoneal 
pressure was measured and ranged between 15.5 and 
22 cm H20  (n = 7), The intraperitoneal pressure in the 
control group with an intraperitoneal volume of 40 w U  
kg BW was 9.5 -1 7  cm H20  (n = 9).
It is concluded that pediatric peritoneal equilibra­
tion tests should be performed with an intraperitoneal 
volume scaled to body surface area so that fluid 
kinetics in different age groups (> 3 years) are com­
parable. Studies in younger children, especially in­
fants, should also be performed. In these younger
children the age relation will be especially interest­
ing because limited observations suggest a decreased 
ultrafiltration capacity at that age (14).
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A Prospective Study of Vancomycin- 
(Vancoled-) Induced Chemical Peritonitis 
in CAPD Patients
Vancomycin has been an important antibiotic in 
the treatment of gram-positive bacterial infections 
since its availability in 1956. It has also been ac­
cepted as one of the first-line antibiotics for the 
treatment of peritonitis in chronic ambulatory peri­
toneal dialysis (CAPD) patients. It has been reported 
that some CAPD patients receiving intraperitoneal 
vancomycin have developed chemical peritonitis (1- 
4) manifesting as turbid effluent 3 to 6 hours after 
administration of the drug (5,6). However, the un­
derlying mechanism responsible for this reaction has 
not been defined. There are studies suggesting that
generic preparations of vancomycin may result in a 
higher incidence of chemical peritonitis when com­
pared with the original formulation (1,4,5). The au­
thors of those studies have postulated that this might 
be related to the greater amount of impurities in 
generic preparations (5). However, this phenomenon 
is not universally recognized, and the exact incidence 
remains unknown (7,8).
While witnessing a less than 1% incidence of 
chemical peritonitis when we were using Vancocin 
(Eli Lilly,Indianapolis, IN, U.S,A.), we noted a defi­
nite increase in such incidence in our CAPD popula­
tion since we changed to the use of a different prepa­
ration, Vancoled (Lederle, Wayne, NJ, U.S.A.), in 
1995. We have therefore performed a prospective 
study ofVancoled-induced chemical peritonitis among 
our CAPD patients to define the incidence and char­
acteristics of such peritonitis and, hopefully, to un­
derstand more about the underlying mechanism,
PATIENTS AND METHODS
Between 1 October 1995 and 29 February 1996,26 
consecutive CAPD patients requiring treatment with 
intraperitoneal vancomycin for either exit-site infec­
tion or peritonitis were recruited prospectively into 
the study. CAPD was performed as per our routine 
using 3 to 4 daily 2-L exchanges of 1.5 -  4.25% 
Dianeal (Baxter, IL, U.S.A.) solution. For patients 
with suspected bacterial peritonitis who had re­
ceived intraperitoneal antibiotic therapy, the 
peritoneal drainage fluid had to become clear [con­
firmed by microscopy with a white cell count (WBC) 
below 100/mm3] before they were recruited and stud­
ied for their response to the second weekly dose of 
intraperitoneal vancomycin. All patients recruited 
had had a history of exposure to vancomycin because 
it is our standard practice to prescribe an intrave­
nous dose of vancomycin as a prophylaxis for 
Tenckhoff catheter insertion, unless contraindicated. 
Patients who required co-administration of other 
intraperitoneal agents apart from heparin, and those 
with a duration of CAPD less than 3 months were 
excluded from the study. There was no restriction on 
the number of occasions studied for any patient so 
that we could also study the consistency of the indi­
vidual response to the drug.
Prior to the administration of intraperitoneal 
vancomycin, 30 mL of peritoneal fluid was obtained 
using strict aseptic procedure for baseline analysis 
including routine microscopy and culture. Centri­
fuged deposits of 20 mL of effluent were used for 
culture using McConkey and blood agars and thio- 
glycollate-enriched broth. Vancoled powder (Lederle, 
Wayne, NJ, U.S.A.) was dissolved in sterile water at 
a concentration of 100 mg/mL for injection. The solu-
202
